Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.
about
New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncologyStructural basis for resistance to diverse classes of NAMPT inhibitorsStructure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drugSolid-phase synthesis of a library of amphipatic hydantoins. Discovery of new hits for TRPV1 blockade.Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells.Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapyDiscovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferaseDiscovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT.Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activationNF-kappa B as a target for cancer therapy.Visfatin/Nampt: an adipokine with cardiovascular impactRegression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartmentsDependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618Nampt: linking NAD biology, metabolism and cancer.Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.The role of inflammation in the pathogenesis of lung cancer.PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?NF-κB in cancer therapy.EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.Crystal structure-based comparison of two NAMPT inhibitors.Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension.Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer.Visfatin/PBEF/Nampt: A New Cardiovascular Target?Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
P2860
Q26745678-0E435778-5F7E-48E3-BA55-B0098A91A9BDQ28543568-4B033367-C43B-49EE-81D1-B2CEE019D92AQ33475966-3C0B5E0C-03F5-493A-B3C5-9096153F4974Q33931937-906E31F5-92A7-47A3-8E86-BF4698B87196Q34328772-98C6D2D3-7AD1-4AB3-BC2F-746F8DB90517Q34482044-56F278EB-752B-4011-BEEF-C90E2E4499A5Q34596902-E3ECBF11-6227-42C3-BF17-1E6FE6B6B675Q35652041-8E451535-026A-47F1-9A11-EE3647192F9DQ35727985-D6E09DE1-DDE4-40C6-9FE5-DC680068388BQ36435313-694B989D-7BF5-4C77-9899-4C395AE0EE71Q36709532-FEC00666-5B52-4C07-9097-98C8768AA9DCQ36970010-BF3AE58C-F326-4112-9AAE-5993415F31F1Q37154811-10E79B21-FF99-4184-A5AA-14A52FE3D6C0Q37285546-839F2186-176F-4299-AE6B-55972F1593A6Q37334248-B6490101-2D5F-4E6B-9037-C7244EB5F834Q37448050-384F6E3A-E31F-47BF-A1CD-CE8D4E3C94AEQ37900640-0CD6EB90-BF96-45E1-BBE5-F18917D5227FQ38005192-018B4685-DEFA-4440-B0F9-96B7EEC8965CQ38359190-FB032E40-059A-4D80-B367-0AAE7F7B92C2Q38405687-87A7572E-03E1-4B92-8976-A7802BB73147Q38635017-8C9928E4-9E38-47DA-AA44-12FA59F34C88Q38736710-20E94378-445F-447E-A5DD-05AAD9BF3416Q38928592-EB330265-27F6-4207-BAE2-9D5F975627F9Q38959459-BBCA3A1A-3762-439D-9E7B-C780C29C912BQ39558774-384442F6-A8FB-4F63-BC0B-D6EAAB514FC8Q39767098-0886D662-27A0-4763-A23B-C7CD948F7EFAQ42727741-D48AC025-D27F-4774-A23D-90FCE51C1543Q51760444-2195E400-A86F-4F96-9AC8-15158B860AB7
P2860
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phase I study and pharmacokine ...... tumours: an ECSG/EORTC study.
@ast
Phase I study and pharmacokine ...... tumours: an ECSG/EORTC study.
@en
Phase I study and pharmacokine ...... tumours: an ECSG/EORTC study.
@en-gb
type
label
Phase I study and pharmacokine ...... tumours: an ECSG/EORTC study.
@ast
Phase I study and pharmacokine ...... tumours: an ECSG/EORTC study.
@en
Phase I study and pharmacokine ...... tumours: an ECSG/EORTC study.
@en-gb
prefLabel
Phase I study and pharmacokine ...... tumours: an ECSG/EORTC study.
@ast
Phase I study and pharmacokine ...... tumours: an ECSG/EORTC study.
@en
Phase I study and pharmacokine ...... tumours: an ECSG/EORTC study.
@en-gb
P2093
P1476
Phase I study and pharmacokine ...... tumours: an ECSG/EORTC study.
@en
P2093
Binh Nguyen Bui
Catherine Terret
Chris Twelves
Dagmar Hess
Jantien Wanders
Jean-Pierre Droz
Pierre Fumoleau
Thomas Cerny
P304
P356
10.1016/J.EJCA.2004.12.023
P577
2005-03-01T00:00:00Z